Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | TACR2 | P21452 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1086607 | 0.89 | TSHR (0.47) | TSHRLMNAGRM2SMN1; SMN2TACR2 | |
| SCHEMBL1086562 | 0.88 | TACR2 (0.36) | TSHRGRM2TACR2TACR1 | |
| SCHEMBL1086846 | 0.86 | TSHR (0.43) | TSHRLMNAGRM2SMN1; SMN2TACR2 | |
| SCHEMBL4486406 | 0.85 | MGLL (0.42) | GRM2SMN1; SMN2HSD11B1 | |
| SCHEMBL1086781 | 0.83 | TACR2 (0.40) | GRM2TACR2TACR1 | |
| SCHEMBL1086697 | 0.82 | HTT (0.44) | TSHRTACR2TACR1ALDH1A1CYP2C19 | |
| SCHEMBL4486191 | 0.82 | MMP13 (0.40) | GRM2TACR2TACR1 | |
| SCHEMBL4498487 | 0.81 | GRM2 (0.41) | TSHRLMNAGRM2SMN1; SMN2TACR2 | |
| SCHEMBL1086594 | 0.81 | TSHR (0.40) | TSHRLMNAGRM2ALDH1A1HSD11B1 | |
| SCHEMBL1086111 | 0.81 | TSHR (0.45) | TSHRLMNAGRM2SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153795-B2 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-compounds and the use thereof for producing drugs | GRUENENTHAL GMBH (DE) | 2012-04-10 | — | — | US | disclosed |
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | GRUENENTHAL GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | DDO, DAO, OTC | TSHR 3698/4885LMNA 3413/4885GRM2 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.